Compared with traditional Chinese medicines with thousands of years of history, Chinese medicine injections that came out in 1941 are innovative formulations. However, because they have the advantages of rapid action, precise treatment, etc. It has become the largest dosage form in the field of traditional Chinese medicine. It is understood that among the top 10 products in the market share of cardio-cerebrovascular and anti-cancer proprietary Chinese medicines, there are 7 seats of traditional Chinese medicine injection products.

According to public information, the compound annual growth rate of TCM injections for the past five years is about 21%, which is significantly higher than the 15.78% for Chinese patent medicines and 18.23% for the entire pharmaceutical market. At present, more than 50 varieties are commonly used, and the overall market size is approximately 25 to 30 billion yuan.

With the rapid development of traditional Chinese medicine injections, its status in the industry has not been in the field of traditional Chinese medicine. According to the tracking data of CITIC Securities, 3 Chinese medicine injections, namely Xueshuantong, Danhong, and Shuxuetong, were among the top 10 branded medicines purchased by domestic sample hospitals in 2009; in 2010, these three varieties had risen to No. 2. 3, 4 digits.

CI Chao Securities researcher Li Chao believes that in the pharmaceutical industry, a single species of billions of dollars is not easy, but the exception is traditional Chinese medicine injections. Terminal sales of Xueshuantong, Danhong, Ginkgo injectables, Xingnaojing, and Tanshinone IIa are expected to exceed 2 billion yuan in 2011; and Kangyin Pharmaceutical’s hot toxin, Xiefeng’s Xiyanping and Shanghai Kai The future ceiling of Bao's geese and other varieties is about 2 billion yuan.

“Traditional Chinese medicine injections have become the market segment with the deepest moats in the pharmaceutical industry, the highest ceilings, and the most vulnerable to pounds.” Li Chao said that in the medium term, the exclusive varieties of traditional Chinese medicine injections and chemical patent medicines have similar properties and are highly Chinese patented drugs that grow genes, those that have good varieties, strong sales ability, and sufficient government resources will stand out from the rest, and they are advised to pay attention to the listing of Shanghai Kaibao, Kangyuan Pharmaceutical, Tasly, Hongri Pharmaceutical and Yiwei Pharmaceutical. the company.

The 2012 mid-year report issued by Shanghai Kaibao on July 20 showed that in the first half of the year, the company achieved operating income of 565 million yuan, a year-on-year increase of 43.22%; net profit attributable to shareholders of listed companies was 120 million yuan, a year-on-year increase of 44.09%; operating cash flow was net The amount of 150 million yuan, a substantial increase of 98.25%. Among them, Tanreqing Injection contributed more than 99% of revenue, gross margin reached 83.77%, an increase of 1.37 percentage points year-on-year.